Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide and Prednisone Maintenance in Multiple Myeloma Post-ASCT
NCT00049673Phase 3Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- Oct 2002
- Primary completion
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of thalidomide in multiple myeloma (MM) (2 arms), sponsored by Canadian Cancer Trials Group. Primary endpoint: Overall Survival at 9 years. Started Oct 2002; status: completed.
02
Drugs
thalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00049673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00049673.